Funding
← Back to your selection

Gaingels

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026

Gaingels co-invests alongside venture leads in companies committed to diverse and inclusive teams, spanning seed through growth and pre-IPO rounds across technology, healthcare and consumer markets.

Its investor community includes LGBTQ+ people and allies, extending representation within the ownership of venture-backed companies. Portfolio companies work with its Gaingels Letter commitments and Venture Inclusion programme on building more inclusive organisations.

A board access programme provides free recruitment advice for diverse board members and observers. This gives founders a practical governance resource alongside a co-investment partner for a round led by another venture firm.

Sources
Rounds participated in
8
Confirmed lead rounds
0
2 roles undisclosed
New companies
8
First participation on record · 0 follow-on
Funding in participating rounds
$130.5M
7 disclosed · full round size, not this investor’s share

By stage

Seed3
Series B3
Undisclosed2

By primary sector

Healthtech3
Fintech2
Biotech1
Climate tech1
Enterprise software1

By country

United States7
1

Rounds

8 in this selection
Charter Space

Charter is a licensed insurance brokerage focused on space and defense companies, placing coverage for spacecraft, launch missions and the businesses behind them.

$5MSeed
Participant
Tiny Health

Tiny Health provides gut and vaginal microbiome testing and analysis to help families understand microbiome health across life stages.

$33MSeries B
Participant
MoneyStack

MoneyStack provides financial counselling within behavioural-health programmes, helping people address money problems alongside treatment.

$1MUndisclosed
Participant
Metal

An AI fundraising workspace that helps founders identify investors, research firms and manage venture rounds.

$4.5MSeed
Participant
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Molten Salt Solutions

Lithium isotope enrichment technology for the fuel needs of advanced fission and fusion reactors.

$7MSeed
Participant
Standard Metrics

AI-driven portfolio management platform for VC and private equity firms

$20MSeries B
Role not disclosed